Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by bull1986on May 26, 2021 1:18pm
113 Views
Post# 33268481

RE:RE:RE:RE:RE:RE:RE:RE:Biotech

RE:RE:RE:RE:RE:RE:RE:RE:BiotechI would suggest that the pre-portal vein top-up results were pretty great. Keeping a brittle diabetic's blood sugar level within a range that excludes hypo/hyperglycemic events is a success. A first-in-world success. Hyperglycemia causes all of the horrible long term side effects of the disease. Hypoglycemia can result in a coma or death and is the reason diabetics often keep their daily blood sugar levels too high. Avoiding these events would materially change life expectancy and quality of life. Given that the Edmonton Protocol is the standard of care for islet transplantation, it's no surprise it was done. It appears to me that they are getting quite close to a functional cure without a top-up. That would be the holy grail. 
<< Previous
Bullboard Posts
Next >>